Aeglea BioTherapeutics Reports Second Quarter 2019 Financial Results and Corporate Highlights
FDA Breakthrough Therapy Designation Received for Pegzilarginase in Treatment of Arginase 1 Deficiency Dosed First Patient in Global Pivotal Phase 3 PEACE Trial New Data from Arginase 1 Deficiency Phase 2 Extension Trial Expected in September 2019 AUSTIN, …